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Background and Aim: 
 
Metronidazole and tetracycline-based second-line




 infection, often ends up in
failure due to antibiotic resistance and poor compliance in Korea. Our aim is to
evaluate the efficacy and tolerability of moxifloxacin-based triple therapy as an













initial proton pump inhibitor triple therapy had failed. They were randomized
to receive the following 7-day therapy: 1, moxifloxacin 400 mg q.d., esome-
prazole 20 mg b.i.d., and amoxicillin 1 g b.i.d.; and 2, esomeprazole 40 mg b.i.d.,
tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d.,
and tetracycline 500 mg q.i.d. Eradication rates, drug compliance, and side-




The eradication rates were 75.6 and 83.8% with moxifloxacin triple









 .260), respectively. Moxifloxacin triple





 .039). Compliance for therapy, i.e., the percentage of tablets taken
(> 85%), was 90.2 and 75.0%, numerically higher in moxifloxacin triple









Moxifloxacin-based triple therapy showed high eradication rates
with few side effects and good drug compliance, suggesting this regimen could
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 infection plays the major role in the
pathogenesis of peptic ulcer disease, chronic gastritis, gastric
mucosa-associated lymphoid tissue (MALT) lymphoma,
and in gastric cancer [1]. Therefore, eradication of the
bacteria has become the main therapy for these diseases.
Worldwide consensus conferences have recommended
triple therapy consisting of a proton pump inhibitor (PPI)
and two antibiotics, mainly amoxicillin and clarithro-
mycin, as first-line eradication therapy [2,3]. Although
this treatment has been shown to be effective in numerous
clinical trials, several meta-analysis revealed that the rates
of eradication were widely variable, ranging from 70 to




 eradication therapy is
necessary for patients with first-line failure, for whom the
Maastricht 2-2000 Consensus Report recommended
the use of minimum 7-day, PPI, bismuth, metronidazole
and tetracycline-based quadruple therapy [2]. However,
this regimen may vary in efficacy in different patient
populations. Although a recent meta-analysis showed that
such treatment for 10–14 days is highly effective [6], in
some countries or areas including Korea, the quadruple
therapy has been also associated with eradication failure
in more than 20% of cases [5,7–10]. The main causes of
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countries are thought to be poor patients’ compliance and
bacterial resistance [5,8–11]. The quadruple therapy entails
complicated dosing schedules in terms of the number
of tablets and interval of administrations. Moreover,
considerable side-effect rates of metronidazole and





 resistance to metronidazole
has a negative impact on quadruple therapy [13,14]. High




 to metronidazole worldwide,
especially in Korea [15–20], has made the efficacy of
metronidazole-containing quadruple therapy limited as
a second-line therapy. Recent Korean reports revealed
the eradication rates of a metronidazole- and tetracycline-
containing second-line therapy were lower than 65% by
intention-to-treat (ITT) analysis and 80% by per-protocol
(PP) analysis [8–10]. Consequently, many therapeutic
options with favorable compliance and various eradication





 eradication failure are still uncertain.
The new generation fluoroquinolones have shown




[24–26], especially in terms of safety, simplicity of dosing
schedule, and high efficacy as the initial eradication ther-
apy. Recently, we have experienced excellent results con-
cerning efficacy and tolerability using moxifloxacin-based
triple therapy in small series of patients with two succes-
sive eradication failures [8]. With this background, we
investigated whether this moxifloxacin-based triple
therapy could be a strong candidate for the second-line






We consecutively enrolled patients, in whom a first
eradication trial with PPI–amoxicillin–clarithromycin




 infection, at Seoul National
University Bundang Hospital in Korea. Patients with
concurrent critical illnesses, a history of previous upper
gastrointestinal surgery, contraindication to any of the
study medication, recent frequent intake of nonsteroidal
anti-inflammatory drugs (NSAIDs), anticoagulants or
steroids, an allergy to the study medications, and who
were pregnant or breast-feeding women were excluded
from the study. Other exclusion criteria included recent use
of antimicrobials and any condition probably associated
with poor compliance such as drug abusers or alcoholics.
All patients enrolled in the study were aware of the study
protocol and agreed to comply with the follow-up
schedule, and all provided written informed consent. The
study was approved by the Ethics Committee of Seoul




Patients were considered as initial treatment failure if any




C-urea breath testing was
positive before study. They were randomly assigned to one
of the following two 1-week treatment regimens: 1, MEA:
moxifloxacin 400 mg q.d., amoxicillin 1000 mg b.i.d., and
esomeprazole 20 mg b.i.d.; and 2, EBMT: esomeprazole
20 mg b.i.d., tripotassium dicitrate bismuthate 300 mg
q.i.d., metronidazole 500 mg t.i.d., and tetracycline
500 mg q.i.d. One week after the completion of therapy,
compliance with therapy was evaluated by a physician
both by being questioned and by pill count. The drug
compliance was considered good if drug intake was
more than 85%. All patients were interviewed for adverse




 eradication was defined











The patient fasted for 4 hours before the test. No test meal
was given, and a predose breath sample was obtained.









Isotechnika, Edmonton, Canada) dissolved in 50 ml of water
was administered orally. The second breath sample was
collected at 30 minutes. The cut-off value used was 4‰ [27].
Collected samples were analyzed by means of isotope ratio








 eradication efficacy were performed
on an ITT basis (included all patients enrolled in the study)
and on a PP basis (excluding patients with poor compliance
for therapy and unavailable data after therapy). The 95%
confidence intervals (CI) for the differences of eradication
rates between the two groups were calculated using












Fisher’s exact test. Analyses were performed using
SPSS (Statistical Package for the Social Sciences version




 < .05 was considered






Eighty-five patients were enrolled in the study from June
2004 through April 2005. Of these, 41 patients were
randomized to the MEA group and 44 patients to the
EBMT group. The baseline characteristics were similar in
 


















the two treatment groups (Table 1). All of them were
included in the ITT analysis. Fifteen patients were excluded
from the PP analysis; that is, follow-up loss and inadequate
post-treatment assessment (no final UBT result) in 10
patients and protocol violation in five patients (the
discontinuation of medication due to adverse events).
Thus, 37 patients in the MEA group and 33 patients in the
EBMT group comprised the study group for inclusion
in the PP analysis. Figure 1 shows the disposition of all










 at the end of follow-up
phase were 75.6% (95% CI) in the MEA group and 54.5%





 eradication was achieved in 83.8% in




eradication rates in the MEA group were significantly











Adverse Events and Compliance
 
Adverse events were described in 4 of 41 patients (9.8%)
in the MEA group and in 12 of 44 patients (27.3%) in
the EBMT group; the most common one was epigastric
discomfort (Table 3). Side-effect rate in the MEA group





Most adverse events were mild to moderate in intensity.
Five serious adverse events were reported and they
were dropped out due to the adverse events. Of these, one
patient was in the MEA group (2.4%) and the adverse
symptom was epigastric pain, and four patients were in
 
MEA group EBMT group p value
Included in ITT analysis (n) 41 44
Male/ female (n) 24/17 23/21 .562a
Mean age ± SD (years) 54.3 ± 11.7 51.6 ± 12.5 .295b
Disease (n) .932a
Gastric ulcer 11 11
Duodenal ulcer 20 24
Gastroduodenal ulcer 2 1
Gastric adenoma or cancer 4 3
Nonulcer dyspepsia 4 5
F/U loss or inadequate UBT assessment (n) 3 7 .316c
ITT, intention-to-treat; SD, standard deviation; F/U, follow-up; UBT, 13C-urea breath test; 
MEA, moxifloxacin + esomeprazole + ˙amoxicillin; EBMT, esomeprazole + bismuth + metronidazole 
+ tetracycline.
aTwo-sided Pearson’s χ2 test.
bTwo-tailed t-test.
cTwo-sided Fisher’s exact test.
Table 1 Baseline demographic characteristics
of patients
Figure 1 Flow diagram of the progress of patients included in intention-
to-treat and per-protocol analysis. ITT, intention-to-treat; PP, per-protocol;
MEA, moxifloxacin + esomeprazole + amoxicillin; EBMT, esomeprazole +
bismuth + metronidazole + tetracycline; F/U, follow-up; UBT, 13C-urea breath
test.
Table 2 Helicobacter pylori eradication rates
 
 
MEA EBMT p value
ITT analysis
Eradication rate 75.6% (31/41) 54.5% (24/44) .042a
95% CI 62.5–88.7% 39.8–69.2%
PP analysis
Eradication rate 83.8% (31/37) 72.7% (24/33) .260a
95% CI 71.9–95.7% 55.7–89.7%
ITT, intention-to-treat; PP, per-protocol; CI, confidence interval; MEA, 
moxifloxacin + esomeprazole + amoxicillin; EBMT, esomeprazole + bismuth
+ metronidazole + tetracycline.
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the EBMT group (9.1%); two patients had epigastric pain,
and the other two showed vomiting and paresthesia,
respectively.
Compliance for therapy, i.e., the percentage of tablets
taken (> 85%), was 90.2% (37/41 patients) and 75.0%
(33/44 patients) in the MEA and EBMT groups, which









Quadruple therapy containing PPI, bismuth, tetracycline,
and metronidazole has been generally used as a second-
line therapy after initial eradication failure and chosen as
the recommended regimen in several guidelines [2,3].
However, this regimen has been associated with eradic-
ation failure in more than 20% of the cases by PP analysis
in some areas including Korea, the main cause of which
is thought to be bacterial resistance. Moreover, poor
patients’ compliance due to considerable side-effect rates
and complicated dosing schedules has decreased the ITT
eradication rates. To overcome the bacterial resistance and
poor compliance, many potential alternative therapeutic
options with favorable compliance and various eradication
rates have been undertaken [21–23,28–30], but the
selection of an appropriate second-line therapy is still
challenging for the clinician.
The background of our study was that moxifloxacin,
which has several advantages in terms of safety and
simplicity of dosing schedules, could decrease the dropout
of patients during eradication therapy resulting in increase
of the eradication by ITT analysis. In addition, in vitro





quinolones including moxifloxacin [24,31,32]. In vitro
susceptibility study performed in our hospital also revealed




 against moxifloxacin, 5.6%
(3/54) in comparison with 40.7% (22/54) of metronida-
zole (unpublished data), supporting these data. Thus, we
hypothesized that the PP eradication rate of moxifloxacin-
containing regimen could be higher or at least equal to that
of conventional quadruple therapy as a second-line therapy.
To prove this, we compared the efficacy and tolerability of
moxifloxacin-based triple therapy with those of conven-









 eradication rates turned out to be 75.6/
83.8% for the moxifloxacin-based triple therapy and 54.5/
72.7% for the quadruple therapy. The eradication rate of
triple therapy was significantly higher than that of the
quadruple therapy by ITT analysis. Drug side effects were
less common in the triple therapy than in the quadruple
therapy, which might have influenced on the numerical
difference in drug compliance and follow-up loss between
the two groups. This study suggests that moxifloxacin-
based triple regimen is efficacious and tolerable and could
be, therefore, used as an alternative second-line eradication
regimen instead of standard quadruple therapy for patients
who have failed in the initial eradication therapy.
To overcome resistance problems, at least, the evalua-





cross-resistance to nitroimidazoles or macrolides as com-
ponents of retreatment combination therapies seems to be
worthwhile. In addition to moxifloxacin, several antibiot-
ics are suggested as candidates satisfying these conditions.
Rifabutin, another potential candidate antibiotic, has been




[33,34], and rifabutin-based clinical trials have suggested





 eradication [22,35]. However, seve-




therapy especially in Korea, which is still a high endemic
area of tuberculosis. Its high cost, rare but serious side
effect, i.e., neutropenia and thrombocytopenia, and most





 limits its use to patients





cation therapies [21,35]. Besides changing the antibiotics,
it is evident that the prolongation of treatment duration
could cope with resistance problems. A recent meta-analysis
suggested 14-day, metronidazole-containing quadruple





 treatment [6]. It might be
valuable to compare this moxifloxacin-based triple therapy
with 14-day quadruple therapy in the future if the side-
effects and complexity of 14-day quadruple therapy
could be overcome in Korea.
Our study has a limitation in that we did not evaluate
the antibiotic resistance in relation to treatment regimens
and eradication rates. The utility of the culture with








Epigastric discomfort 2 (4.9%) 6 (13.6%)
Nausea or vomiting 1 (2.4%) 2 (4.5%)
Facial spasm or paresthesia – 2 (4.5%)
Diarrhea 1 (2.4%) –
Chest tightness – 1 (2.3%)
Constipation – 1 (2.3%)
Total 4 (9.8%)a 12 (27.3%)
MEA, moxifloxacin + esomeprazole + amoxicillin; EBMT, esomeprazole + 
bismuth + metronidazole + tetracycline.
ap < .05 when compared with the EBMT group (two-sided Pearson’s 
χ2 test).
 


















subsequent antibiotic susceptibility testing and the
moment when it should be performed after eradication
failure are still controversial. However, it gains more
appraisal that culture after a first eradication failure is not
necessary [3,7,21]. It may be pertinent to perform the bac-
terial culture and antibiotic susceptibility testing after two
or more successive failures of eradication. From a practical
viewpoint, we omitted the culture study. Another poten-
tial weakness of our study is that the compliance of quad-
ruple therapy group was poor. The main reason of poor
compliance of quadruple therapy is likely to have origi-
nated from the complexity of tablet-taking times (two,
three, four times per drug) and the high tablet number of
this regimen in Korea. That is, quadruple therapy consists
of esomeprazole 20 mg b.i.d. (2 tablets), tripotassium dici-
trate bismuthate 300 mg q.i.d. (4 tablets), metronidazole
500 mg t.i.d. (250 mg, 6 tablets), and tetracycline 500 mg
q.i.d. (250 mg, 8 tablets) in comparison of MEA: moxi-
floxacin 400 mg q.d. (1 tablet), amoxicillin 1000 mg b.i.d.
(250 mg, 4 tablets), and esomeprazole 20 mg b.i.d. (2
tablets). The tablet number of quadruple therapy is 20,
nearly three times more than that of MEA, which has
seven. In addition, we met the patients only two times
during the second treatment, at the start point of study and
after the completion of regimen, which is reflecting the
usual practice pattern. This was equally applied to both
treatment groups, and the compliance was not statistically
different between moxifloxacin-based therapy and quad-
ruple therapy.
In conclusion, 1-week esomeprazole, amoxicillin,





 eradication therapy, especially, in
terms of safety and tolerability. Further larger studies are
needed to determine the broad application of this eradica-
tion regimen in comparison with currently approved
quadruple, second-line therapy.
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